Chuanlong Cui

Dr. Chuanlong Cui


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Journal of Proteomics
Verified
Journal Article
Closed access
ABAnnie Beuve
Annie Beuve
CWChanggong Wu
Changgong Wu
CCChuanlong Cui
Chuanlong Cui
TLTong Liu
Tong Liu
MJMohit Raja Jain
Mohit Raja Jain
HLHong Li
Hong Li

1 April 2019 in Journal of Proteomics
Verified
Journal Article
Closed access
CCChuanlong Cui
Chuanlong Cui
TLTong Liu
Tong Liu
TCTong Chen
Tong Chen
JLJohanna Lu
Johanna Lu
ICIan Casaren
Ian Casaren
HLHong Li
Hong Li

1 December 2015 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
TLTong Liu
Tong Liu
CWChanggong Wu
Changgong Wu
MJMohit Raja Jain
Mohit Raja Jain
NNNarayani Nagarajan
Narayani Nagarajan
LYLin Yan
Lin Yan
HLHong Li
Hong Li

1 July 2017 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
CWChanggong Wu
Changgong Wu
HDHuacheng Dai
Huacheng Dai
LYLin Yan
Lin Yan
TLTong Liu
Tong Liu
CCChuanlong Cui
Chuanlong Cui
HLHong Li
Hong Li

2 October 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
WYWaqas Younis
Waqas Younis
PBPia C. Burboa
Pia C. Burboa
TSTanaz Sadeghian
Tanaz Sadeghian
VKVeronica Kuzdowicz
Veronica Kuzdowicz
CCChuanlong Cui
Chuanlong Cui
ABAnnie Beuve
Annie Beuve
We previously demonstrated that the NO-stimulated soluble guanylyl cyclase (GC1), which produces cGMP, also has the ability to transfer S-nitrosothiols (SNO) to other proteins in a reaction involving oxidized Thioredoxin 1 (oTrx1). This transnitrosation cascade was established in vitro and involved Cys 610 (C610) of GC1 as the major SNO-donor. To assay the relevance of GC1 transnitrosation under physiological conditions and in oxidative pathologies, we studied a knock-in mouse in which C610 was replaced with a serine (KI αC 610S ) under basal or angiotensin II (Ang II)-treated conditions. Despite similar GC1 expression and NO responsiveness, the Ang II-treated KI mice displayed exacerbated oxidative pathologies including higher mean arterial pressure and more severe cardiac dysfunctions compared to the Ang II-treated WT. These phenotypes were associated with a drastic decrease in global S-nitrosation and in levels of SNO-Trx1 in the KI mice. To investigate the mechanism underlying the dysregulation of blood pressure, pressure myography and in vivo intravital microscopy were conducted to analyze the vascular tone of resistance vessels. Both approaches indicated that, even in the absence of oxidative stress, the single mutation C610S led to a significant disruption of the endothelium-dependent, acetylcholine-induced vasorelaxation while NO-dependent smooth muscle relaxation remained unchanged. Mechanistically, the vasorelaxation defect was associated with decreased endothelial calcium influx and membrane hyperpolarization, independent of NO bioavailability. These findings indicate that the C610S mutation uncouples two NO signaling vasodilatory pathways (endothelial SNO and smooth muscle NO-cGMP) and suggest that GC1 transnitrosation activity is essential for endothelium-derived hyperpolarization.

10 April 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
CCChuanlong Cui
Chuanlong Cui
PSPing Shu
Ping Shu
TSTanaz Sadeghian
Tanaz Sadeghian
WYWaqas Younis
Waqas Younis
HLHong Li
Hong Li
ABAnnie Beuve
Annie Beuve
Soluble guanylyl cyclase (GC1) and oxido-reductase thioredoxin (Trx1) form a complex that mediates two NO signaling pathways as a function of the redox state of cells. Under physiological conditions, reduced Trx1 (rTrx1) supports the canonical NO-GC1-cGMP pathway by protecting GC1 activity from thiol oxidation. Under oxidative stress, the NO-cGMP pathway is disrupted by the S-nitrosation of GC1 (addition of a NO group to a cysteine). In turn, SNO-GC1 initiates transnitrosation cascades, using oxidized thioredoxin (oTrx1) as a nitrosothiol relay. We designed an inhibitory peptide that blocked the interaction between GC1 and Trx1. This inhibition resulted in the loss of a) the rTrx1 enhancing effect of GC1 cGMP-forming activity in vitro and in cells and its ability to reduce the multimeric oxidized GC1 and b) GC1’s ability to fully reduce oTrx1, thus identifying GC1 novel reductase activity. Moreover, an inhibitory peptide blocked the transfer of S-nitrosothiols from SNO-GC1 to oTrx1. In Jurkat T cells, oTrx1 transnitrosates procaspase-3, thereby inhibiting caspase-3 activity. Using the inhibitory peptide, we demonstrated that S-nitrosation of caspase-3 is the result of a transnitrosation cascade initiated by SNO-GC1 and mediated by oTrx1. Consequently, the peptide significantly increased caspase-3 activity in Jurkat cells, providing a promising therapy for some cancers.